How a cancer-fighting Peninsula biotech has sealed 3 collaborations and a big IPO this year

From the Stanford University lab of a cancer immunotherapy pioneer to an IPO, a small-but-growing Peninsula biotech company is looking to continue its win streak with its third biopharma collaboration of the year. Bolt Biotherapeutics Inc. of Redwood City said it will partner with drug giant Bristol-Myers Squibb Co. on a new combination of two of the companies' main drugs that could start a clinical trial yet this year. Bolt's (NASDAQ: BOLT) BDC-1001 will be combined with Bristol-Myers Squibb's…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news